Prediabetes Market Scope, Revenue, Competition and Future Outlook Till 2034
Global Prediabetes Market Growth, Size, Trends Analysis - By Drug Class, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: May-2025 | Report ID: HLCA25145 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
Global Prediabetes Market Introduction and Overview
According to SPER Market Research, the Global Prediabetes Market is estimated to reach USD 1021.93 million by 2034 with a CAGR of 11.19%.
The report includes an in-depth analysis of the Global Prediabetes Market, including market size and trends, product mix, Applications, and supplier analysis.The prediabetes market is growing due to increased insulin resistance and impaired glucose metabolism from gene mutations. Prediabetes, characterized by blood sugar levels between 100 and 125 mg/dL, is increasing the demand for effective treatments. The broad adoption of antidiabetic medications such as Metformin—approved by the FDA in 1994 for reducing glucose production and absorption—plays a key role in supporting market growth. The drug’s accessibility in multiple formulations and combinations also helps drive this trend. Nonetheless, limited awareness and frequent underdiagnosis remain major barriers, as a significant number of individuals are unaware they have prediabetes. The limited availability of FDA-approved treatments specifically for prediabetes also poses a significant challenge.
By Drug Class:
Biguanides dominated the 2024 market (78.8% share) due to Metformin's proven ability to manage blood sugar and improve insulin sensitivity. Its affordability, safety profile, and role in preventing type 2 diabetes progression make it a top choice. Increased prediabetes awareness further boosts demand. Conversely, GLP-1 agonists are projected for rapid growth (19.1% CAGR 2025-2030) due to their effectiveness in glycemic control and reducing diabetes risk.
Age Group Analysis
Adults (18-49) held the largest prediabetes market share in 2024 due to growing awareness and risk factors like inactivity, poor diet, and obesity. This health-conscious group actively seeks preventive care, increasing their likelihood of adopting lifestyle changes or medication. The availability of digital health platforms and wellness programs tailored to this demographic offers convenient management and reversal solutions, significantly contributing to the prediabetes industry's expansion.
Regional Insights:
North America led the prediabetes market in 2024, driven by increased GLP-1 agonist use and a stronger focus on personalized treatments. The effectiveness of GLP-1 agonists in controlling blood sugar and aiding weight loss makes them a popular choice for managing prediabetes. Furthermore, the growing trend of personalized medicine, which considers individual genetic makeup and lifestyle, enables more targeted and successful treatment strategies. These advancements contribute to better prediabetes management and market growth in the region.
Market Competitive Landscape
The competitive landscape in the Prediabetes Market is influenced by both new and established competitors. Some of the key market players are Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.
Recent Developments:
Aphaia Pharma reported positive outcomes in June 2024 from their Phase 2 study of APHD-012, an oral glucose formulation intended for prediabetes. The 6-week trial successfully achieved its main goal, demonstrating notable enhancement in glucose tolerance and a favorable safety record.
In September 2023, Novo Nordisk introduced its weight loss injection, Wegovy, to the UK market. This introduction provided a new and innovative treatment option for individuals managing obesity, expanding the availability of effective weight management solutions in the region.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Drug Class, By Age Group |
| Regions covered | North America, Latin
America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus
Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca,
Bristol-Myers Squibb Company, Pfizer Inc. |
Key Topics Covered in the Report
- Global Prediabetes Market Size (FY’2021-FY’2034)
- Overview of Global Prediabetes Market
- Segmentation of Global Prediabetes Market By Drug Class (Diguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others)
- Segmentation of Global Prediabetes Market By Age Group {(Children (12-18 years), Adults (18-49), Elderly (50+)}
- Statistical Snap of Global Prediabetes Market
- Expansion Analysis of Global Prediabetes Market
- Problems and Obstacles in Global Prediabetes Market
- Competitive Landscape in the Global Prediabetes Market
- Details on Current Investment in Global Prediabetes Market
- Competitive Analysis of Global Prediabetes Market
- Prominent Players in the Global Prediabetes Market
- SWOT Analysis of Global Prediabetes Market
- Global Prediabetes Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPER’s internal database
2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Prediabetes Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Prediabetes Market
7. Global Prediabetes Market, By Drug Class, (USD Million) 2021-2034
7.1. Diguanide
7.2. Thiazolidinediones
7.3. Glucagon-like peptide-1 agonists (GLP-1)
7.4. SGLT2 inhibitors
7.5. DPP-4 inhibitors
7.6. Others
8. Global Prediabetes Market, By Age Group, (USD Million) 2021-2034
8.1. Children (12-18 years)
8.2. Adults (18-49)
8.3. Elderly (50+)
9. Global Prediabetes Market, (USD Million) 2021-2034
9.1. Global Prediabetes Market Size and Market Share
10. Global Prediabetes Market, By Region, 2021-2034 (USD Million)
10.1. Asia-Pacific
10.1.1. Australia
10.1.2. China
10.1.3. India
10.1.4. Japan
10.1.5. South Korea
10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France
10.2.2. Germany
10.2.3. Italy
10.2.4. Spain
10.2.5. United Kingdom
10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia
10.3.2. United Arab Emirates
10.3.3. Qatar
10.3.4. South Africa
10.3.5. Egypt
10.3.6. Morocco
10.3.7. Nigeria
10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada
10.4.2. Mexico
10.4.3. United States
10.5. Latin America
10.5.1. Argentina
10.5.2. Brazil
10.5.3. Rest of Latin America
11. Company Profile
11.1. Novo Nordisk A/S
11.1.1. Company details
11.1.2. Financial outlook
11.1.3. Product summary
11.1.4. Recent developments
11.2. Valbiotis
11.2.1. Company details
11.2.2. Financial outlook
11.2.3. Product summary
11.2.4. Recent developments
11.3. RESVERLOGIX
11.3.1. Company details
11.3.2. Financial outlook
11.3.3. Product summary
11.3.4. Recent developments
11.4. Caelus Health
11.4.1. Company details
11.4.2. Financial outlook
11.4.3. Product summary
11.4.4. Recent developments
11.5. Scimar
11.5.1. Company details
11.5.2. Financial outlook
11.5.3. Product summary
11.5.4. Recent developments
11.6. Boston Pharmaceuticals
11.6.1. Company details
11.6.2. Financial outlook
11.6.3. Product summary
11.6.4. Recent developments
11.7. APHAIA PHARMA AG
11.7.1. Company details
11.7.2. Financial outlook
11.7.3. Product summary
11.7.4. Recent developments
11.8. AstraZeneca
11.8.1. Company details
11.8.2. Financial outlook
11.8.3. Product summary
11.8.4. Recent developments
11.9. Bristol-Myers Squibb Company
11.9.1. Company details
11.9.2. Financial outlook
11.9.3. Product summary
11.9.4. Recent developments
11.10. Pfizer Inc.
11.10.1. Company details
11.10.2. Financial outlook
11.10.3. Product summary
11.10.4. Recent developments
11.11. Others
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Prediabetes Market is projected to reach USD 1021.93 million by 2034, growing at a CAGR of of 11.19% during the forecast period.
Prediabetes Market grew in Market size from 2025. The Market is expected to reach USD 1021.93 million by 2034, at a CAGR of 11.19% during the forecast period.
Prediabetes Market CAGR of 11.19% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Prediabetes Market size is USD 1021.93 million from 2025 to 2034.
Prediabetes Market is covered By Drug Class, By Age Group
The North America is anticipated to have the highest Market share in the Prediabetes Market.
Novo Nordisk A/S, Valbiotis, RESVERLOGIX, Caelus Health, Scimar, Boston Pharmaceuticals, APHAIA PHARMA AG, AstraZeneca, Bristol-Myers Squibb Company, Pfizer Inc.
The report includes an in-depth analysis of the Global Prediabetes Market, including market size and trends, product mix, Applications, and supplier analysis.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
